{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:24:01Z","timestamp":1768321441990,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,2,7]],"date-time":"2013-02-07T00:00:00Z","timestamp":1360195200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2334-13-75","type":"journal-article","created":{"date-parts":[[2013,2,7]],"date-time":"2013-02-07T17:14:16Z","timestamp":1360257256000},"source":"Crossref","is-referenced-by-count":21,"title":["Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands"],"prefix":"10.1186","volume":"13","author":[{"given":"Tjalke A","family":"Westra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Stirbu-Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Dorsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D","family":"Tutuhatunewa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin L","family":"de Vrij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans W","family":"Nijman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toos","family":"Daemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan C","family":"Wilschut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J","family":"Postma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,7]]},"reference":[{"issue":"11","key":"2265_CR1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/cncr.25065","volume":"116","author":"IC Scarinci","year":"2010","unstructured":"Scarinci IC, Garcia FA, Kobetz E, Partridge EE, Brandt HM, Bell MC, Dignan M, Ma GX, Daye JL, Castle PE: Cervical cancer prevention: new tools and old barriers. Cancer. 2010, 116 (11): 2531-2542.","journal-title":"Cancer"},{"issue":"9590","key":"2265_CR2","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","volume":"370","author":"M Schiffman","year":"2007","unstructured":"Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet. 2007, 370 (9590): 890-907. 10.1016\/S0140-6736(07)61416-0.","journal-title":"Lancet"},{"issue":"2","key":"2265_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jcv.2008.11.001","volume":"44","author":"PK Chan","year":"2009","unstructured":"Chan PK, Luk AC, Luk TN, Lee KF, Cheung JL, Ho KM, Lo KK: Distribution of human papillomavirus types in anogenital warts of men. J Clin Virol. 2009, 44 (2): 111-114. 10.1016\/j.jcv.2008.11.001.","journal-title":"J Clin Virol"},{"issue":"9686","key":"2265_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","volume":"374","author":"J Paavonen","year":"2009","unstructured":"Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al: Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009, 374 (9686): 301-314. 10.1016\/S0140-6736(09)61248-4.","journal-title":"Lancet"},{"issue":"7","key":"2265_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1086\/597309","volume":"199","author":"CM Wheeler","year":"2009","unstructured":"Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, et al: The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009, 199 (7): 936-944. 10.1086\/597309.","journal-title":"J Infect Dis"},{"issue":"3","key":"2265_CR6","first-page":"165","volume":"28","author":"A Szarewski","year":"2007","unstructured":"Szarewski A: Prophylactic HPV vaccines. Eur J Gynaecol Oncol. 2007, 28 (3): 165-169.","journal-title":"Eur J Gynaecol Oncol"},{"key":"2265_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-2296-11-39","volume":"11","author":"IV van den Broek","year":"2010","unstructured":"van den Broek IV, Verheij RA, van Dijk CE, Koedijk FD, van der Sande MA, van Bergen JE: Trends in sexually transmitted infections in the Netherlands, combining surveillance data from general practices and sexually transmitted infection centers. BMC Fam Pract. 2010, 11: 39-10.1186\/1471-2296-11-39.","journal-title":"BMC Fam Pract"},{"issue":"4","key":"2265_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/EDE.0b013e31821d107b","volume":"22","author":"JA Bogaards","year":"2011","unstructured":"Bogaards JA, Coupe VM, Xiridou M, Meijer CJ, Wallinga J, Berkhof J: Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology. 2011, 22 (4): 505-515. 10.1097\/EDE.0b013e31821d107b.","journal-title":"Epidemiology"},{"issue":"4","key":"2265_CR9","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/ijc.24000","volume":"124","author":"VM Coupe","year":"2009","unstructured":"Coupe VM, van Ginkel J, de Melker HE, Snijders PJ, Meijer CJ, Berkhof J: HPV16\/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Int J Cancer. 2009, 124 (4): 970-978. 10.1002\/ijc.24000.","journal-title":"Int J Cancer"},{"issue":"15","key":"2265_CR10","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/jnci\/djp183","volume":"101","author":"IM de Kok","year":"2009","unstructured":"de Kok IM, van Ballegooijen M, Habbema JD: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Canc Inst. 2009, 101 (15): 1083-1092. 10.1093\/jnci\/djp183.","journal-title":"J Natl Canc Inst"},{"issue":"35","key":"2265_CR11","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.1016\/j.vaccine.2009.05.085","volume":"27","author":"RM Rogoza","year":"2009","unstructured":"Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T, Wilschut JC, Postma MJ: Cost-effectiveness of prophylactic vaccination against human papillomavirus 16\/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine. 2009, 27 (35): 4776-4783. 10.1016\/j.vaccine.2009.05.085.","journal-title":"Vaccine"},{"issue":"3","key":"2265_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/infdis\/jir281","volume":"204","author":"TA Westra","year":"2011","unstructured":"Westra TA, Rozenbaum MH, Rogoza RM, Nijman HW, Daemen T, Postma MJ, Wilschut JC: Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J Infect Dis. 2011, 204 (3): 377-384. 10.1093\/infdis\/jir281.","journal-title":"J Infect Dis"},{"key":"2265_CR13","first-page":"A356","volume":"153","author":"TA Westra","year":"2009","unstructured":"Westra TA, Daemen T, Postma MJ, Wilschut JC: [Efficiency of human papillomavirus vaccination-estimates based on Dutch cost effectiveness analyses]. Ned Tijdschr Geneeskd. 2009, 153: A356-","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2265_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/1471-2334-9-119","volume":"9","author":"RP Insinga","year":"2009","unstructured":"Insinga RP, Dasbach EJ, Elbasha EH: Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009, 9: 119-10.1186\/1471-2334-9-119.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"2265_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/1097-0215(20000715)87:2<221::AID-IJC11>3.0.CO;2-2","volume":"87","author":"MV Jacobs","year":"2000","unstructured":"Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, Meijer CJ: Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer. 2000, 87 (2): 221-227. 10.1002\/1097-0215(20000715)87:2<221::AID-IJC11>3.0.CO;2-2.","journal-title":"Int J Cancer"},{"issue":"11","key":"2265_CR16","doi-asserted-by":"publisher","first-page":"e3743","DOI":"10.1371\/journal.pone.0003743","volume":"3","author":"CH Lenselink","year":"2008","unstructured":"Lenselink CH, Melchers WJ, Quint WG, Hoebers AM, Hendriks JC, Massuger LF, Bekkers RL: Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS One. 2008, 3 (11): e3743-10.1371\/journal.pone.0003743.","journal-title":"PLoS One"},{"issue":"7","key":"2265_CR17","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/sti.2009.041210","volume":"86","author":"M Kramer","year":"2010","unstructured":"Kramer M, Mollema L, Smits G, Boot H, de Melker H, der Klis FV: Age-specific HPV seroprevalence among young females in The Netherlands. Sex Transm Infect. 2010, 86 (7): 494-499. 10.1136\/sti.2009.041210.","journal-title":"Sex Transm Infect"},{"key":"2265_CR18","doi-asserted-by":"publisher","first-page":"d5775","DOI":"10.1136\/bmj.d5775","volume":"343","author":"M Jit","year":"2012","unstructured":"Jit M, Chapman R, Hughes O, Choi YH: Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2012, 343: d5775-","journal-title":"BMJ"},{"key":"2265_CR19","volume-title":"Guideline for costing research, methods and standardized prices for economic evaluations in health care","author":"JB Oostenbrink","year":"2004","unstructured":"Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH: Guideline for costing research, methods and standardized prices for economic evaluations in health care. 2004, Diemen: Health Care Insurance Board"},{"issue":"8","key":"2265_CR20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/OLQ.0b013e3181a74c2c","volume":"36","author":"SC Woodhall","year":"2009","unstructured":"Woodhall SC, Jit M, Cai C, Ramsey T, Zia S, Crouch S, Birks Y, Newton R, Edmunds WJ, Lacey CJ: Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex Transm Dis. 2009, 36 (8): 515-521. 10.1097\/OLQ.0b013e3181a74c2c.","journal-title":"Sex Transm Dis"},{"issue":"3","key":"2265_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/sti.2007.029512","volume":"84","author":"S Woodhall","year":"2008","unstructured":"Woodhall S, Ramsey T, Cai C, Crouch S, Jit M, Birks Y, Edmunds WJ, Newton R, Lacey CJ: Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect. 2008, 84 (3): 161-166. 10.1136\/sti.2007.029512.","journal-title":"Sex Transm Infect"},{"issue":"5","key":"2265_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/jnci\/djp534","volume":"102","author":"N Munoz","year":"2010","unstructured":"Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, et al: Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women. J Natl Canc Inst. 2010, 102 (5): 325-339. 10.1093\/jnci\/djp534.","journal-title":"J Natl Canc Inst"},{"issue":"7","key":"2265_CR23","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/IGC.0b013e3181a3d100","volume":"19","author":"LR Medeiros","year":"2009","unstructured":"Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR: Efficacy of human papillomavirus vaccines: a systematic quantitative review. Int J Gynecol Canc. 2009, 19 (7): 1166-1176. 10.1111\/IGC.0b013e3181a3d100.","journal-title":"Int J Gynecol Canc"},{"issue":"10","key":"2265_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","volume":"12","author":"T Malagon","year":"2012","unstructured":"Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M: Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012, 12 (10): 781-789. 10.1016\/S1473-3099(12)70187-1.","journal-title":"Lancet Infect Dis"},{"issue":"3 Suppl","key":"2265_CR25","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ygyno.2009.01.011","volume":"115","author":"MP David","year":"2009","unstructured":"David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, Van Damme P: Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol. 2009, 115 (3 Suppl): S1-S6.","journal-title":"Gynecol Oncol"},{"key":"2265_CR26","unstructured":"Pharmacoeconomic guidelines around the world. The Internaltional Society of Pharmacoeconomics and Outcomes Research: http:\/\/www.ispor.org\/peguidelines\/index.asp [accessed April 2011]"},{"issue":"10","key":"2265_CR27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.4161\/hv.5.10.9518","volume":"5","author":"MH Einstein","year":"2009","unstructured":"Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, et al: Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009, 5 (10): 705-719. 10.4161\/hv.5.10.9518.","journal-title":"Hum Vaccin"},{"issue":"11","key":"2265_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1473-3099(08)70258-5","volume":"8","author":"P Beutels","year":"2008","unstructured":"Beutels P, Scuffham PA, MacIntyre CR: Funding of drugs: do vaccines warrant a different approach?. Lancet Infect Dis. 2008, 8 (11): 727-733. 10.1016\/S1473-3099(08)70258-5.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"2265_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2165\/11539960-000000000-00000","volume":"29","author":"M Jit","year":"2011","unstructured":"Jit M, Brisson M: Modelling the epidemiology of infectious diseases for decision analysis: a primer. PharmacoEconomics. 2011, 29 (5): 371-386. 10.2165\/11539960-000000000-00000.","journal-title":"PharmacoEconomics"},{"issue":"5","key":"2265_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1586\/erv.12.30","volume":"11","author":"MJ Postma","year":"2012","unstructured":"Postma MJ: Dynamic modeling for pandemic influenza. Expet Rev Vaccine. 2012, 11 (5): 543-546. 10.1586\/erv.12.30.","journal-title":"Expet Rev Vaccine"},{"issue":"5","key":"2265_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/sti.2008.034793","volume":"85","author":"SR Morris","year":"2009","unstructured":"Morris SR: HPV vaccine strategies: the cost of HPV and the choice of vaccine. Sex Transm Infect. 2009, 85 (5): 315-316. 10.1136\/sti.2008.034793.","journal-title":"Sex Transm Infect"},{"key":"2265_CR32","doi-asserted-by":"publisher","first-page":"d5775","DOI":"10.1136\/bmj.d5775","volume":"343","author":"M Jit","year":"2011","unstructured":"Jit M, Chapman R, Hughes O, Choi YH: Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2011, 343: d5775-10.1136\/bmj.d5775.","journal-title":"BMJ"},{"key":"2265_CR33","doi-asserted-by":"publisher","first-page":"a769","DOI":"10.1136\/bmj.a769","volume":"337","author":"M Jit","year":"2008","unstructured":"Jit M, Choi YH, Edmunds WJ: Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008, 337: a769-10.1136\/bmj.a769.","journal-title":"BMJ"},{"issue":"5","key":"2265_CR34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jval.2012.02.012","volume":"15","author":"N Demarteau","year":"2012","unstructured":"Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G: Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan. Value Health. 2012, 15 (5): 622-631. 10.1016\/j.jval.2012.02.012.","journal-title":"Value Health"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-13-75\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-75.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-75","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-75.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T18:13:12Z","timestamp":1714932792000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-13-75"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2265"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-13-75","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,7]]},"article-number":"75"}}